Navigation Links
Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
Date:10/1/2007

- Former Research Team Director and Key Strategy Architect to Build on

Foundation's Momentum In Pursuing Systemic Changes to Advance in

Parkinson's Disease Treatments -

NEW YORK, Oct. 1 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced that Katie Hood, Deputy Chief Executive Officer and former Research Director, has been appointed Interim Chief Executive Officer. Ms. Hood, who joined the Foundation in September 2002, has played critical roles in shaping its strategy of intervening aggressively to close critical gaps in the process of moving potential treatments from the laboratory to Parkinson's patients, as well as in building a team of in-house research experts needed to implement that strategy.

Ms. Hood replaces CEO Sarah Orsay, who is leaving MJFF in order to devote more time to her three children.

MJFF Founder Michael J. Fox said, "The Michael J. Fox Foundation has grown enormously in our sophistication and in our capability to work with everyone from academic researchers to industry in plugging the many gaps in the process that keep promising science from advancing to effective, life-changing treatments for Parkinson's. Katie Hood has played a big part in that evolution, and we're confident that with her at the helm, we will not only maintain our momentum but will continue to build our reputation for not just throwing money at the problem, but truly taking a leadership role in helping identify and cultivate research breakthroughs."

Ms. Hood stated, "After five years working with management and staff at all levels of MJFF, as well as our scientific advisors, grantees, industry partners and donors, I am looking forward to working with Michael, our Board and our entire team to further advance the mission and strategy of a foundation that is increasingly setting the standard for effectiveness and best business practices."

As Interim Chief Executive Officer, Ms. Hood will provide day-to-day management and oversight of all Foundation activities and will specifically oversee fundraising, the Foundation's research team and communications, administration and financial management. Ms. Hood will report to the Board of Directors. Debi Brooks will continue to serve as co-founder with a focus on principal-gifts fundraising and outreach to key external audiences, reporting to the Board of Directors.

The Foundation stated that Ms. Hood will be a candidate to assume the CEO position on a permanent basis.

Prior to joining the Foundation, Ms. Hood was employed as a consultant at Bain & Company in New York City, doing work in the consumer products, financial services, and nonprofit sectors. She has also served as an analyst in the Credit Department of Goldman, Sachs & Co., and as a program coordinator with Duke University's Hart Leadership Program. Ms. Hood graduated from Harvard Business School, and holds a BA in Public Policy Studies from Duke University in Durham, North Carolina.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded more than $95 million in research to date, either directly or through partnerships. For more information please visit the Foundation's Web site at http://www.michaeljfox.org.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Katee Holmes Vs Katie Holmes Case of Losing Virginity
2. Katie Holmes in most Influential Celebs List
3. Wood Appointed As the First Chair of SAADAT
4. Yoga Guru appointed Bihars brand ambassador
5. Disappointed Students Plan To Intensify Agitation Nationwide
6. City Surgeon Appointed Adviser To Armed Forces
7. Indian-American Appointed for US Hospital Top Post
8. Retiring Government Doctors to Be Reappointed to Overcome Paucity of Specialists
9. Bruce Vladeck Will Hold Fort (interim) of UMDNJ
10. Interim WHO Chief Confirms No radical changes in WHO
11. Interim OPD saves the day for patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... , ... Husted Kicking has completed its Third Annual Husted Kicking ... 7th, 2016 according to kicking coach Michael Husted. , “This event serves as an ... in Indianapolis,” says Husted. “The NFL uses a third party organization to select players ...
(Date:2/10/2016)... ... 2016 , ... President Obama’s budget proposal yesterday enables the ... services via telehealth, estimated to generate more than $160 million in savings over ... years. Although there is more to be done, this represents an important ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... health care communications company offering education, research and medical media, has launched ... specialists working in infectious diseases. , As the all-inclusive resource for infectious ...
(Date:2/10/2016)... NASHVILLE, Tenn. (PRWEB) , ... February 10, 2016 ... ... by the American Academy of Emergency Medicine , an emergency medicine ... of practice management services . , The American Academy of Emergency Medicine, ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... announces that his office is now offering a variety of comprehensive procedures for ... enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. , ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... -- --> --> ... Spectroscopy Market by Industry (Oil & Gas, Petrochemical, Pharmaceutical, Water ... & Mining, and Others), And Geography - Global Forecast ... expected to grow to USD 3.9 Billion by 2020, ... 2020. Browse 82 market data Tables and ...
(Date:2/10/2016)... Feb. 10, 2016  Resolve Therapeutics, LLC, a ... approaches to the treatment of lupus and Sjogrens ... multiple ascending dose study in patients with systemic ... --> --> ... ascending dose study of RSLV-132 in 32 subjects ...
Breaking Medicine Technology: